STUDIES
A Joint Value of Treatment Study on Anorexia Nervosa, Autism and Depression in Europe
Early Detection and Continuity of Care: A Joint Value of Treatment Study on Anorexia Nervosa, Autism and Depression in Europe. Part of the 2nd Round of the Value of Treatment for Brain Disorders in Europe study, this document outlines the results of the case studies on mental disorders.
A Joint Value of Treatment Study on Rare Neurological and Neurometabolic Disorders in Europe
Bridging Gaps and Achieving Seamless, Coordinated Care: A Joint Value of Treatment Study on Rare Neurological and Neurometabolic Disorders in Europe. Part of the 2nd Round of the Value of Treatment for Brain Disorders in Europe study, this document outlines the results of the case studies on rare neurological and neurometabolic disorders Ataxia, Dystonia and Phenylketonuria.
RETHINKING MS in times of COVID-19
The objective of “RETHINKING MS in times of COVID-19” is to provide concrete and tangible testimonies from relevant stakeholders – clinicians, MS patients, patient advocates, pharma representatives – impacted by the disruption in care, which proved both an obstacle and an accelerator for the implementation of good practices.
RETHINKING MS in Europe
RETHINKING MS in Europe is a project calling for change in how multiple sclerosis (MS) care and support is organised. This pan-European policy narrative identifies key challenges in MS care and makes recommendations for how they can be addressed.
‘The Value of Treatment of Brain Disorders in Europe’ Research Project
Consensus Document on European Brain Research
In 2006 EBC published a Consensus Document on European Brain Research, describing needs and achievements of research in Europe and presenting proposals for future research programs. The document underwent a major revision in 2011 and another one in 2015. The present document represents an update elaborated to reflect changes in research priorities and advances in brain research that have taken place since 2006.
Cost of Disorders of the Brain in Europe 2010
“Cost of disorders of the brain in Europe 2010” is the direct successor of a benchmark study of the same title published in 2005. The success of the 2005 study, in alerting European politicians and policy makers to the prevalence and high cost of brain diseases as well as the low levels of associated research funding, demanded the publication of a follow-up report. Both studies were commissioned by EBC.
Associated Studies
The economic cost of brain disorders in Europe 2010
The economic cost of brain disorders in Europe 2010 builds up on the findings from the ‘Cost of disorders of the brain in Europe 2005’ and presents updated, more accurate, and comprehensive 2010 estimates for 30 European countries. The cost model reveals that brain disorders overall are much more costly than previously estimated constituting a major health economic challenge for Europe.
The size and burden of mental disorders and other disorders of the brain in Europe 2010
A major landmark study released on the 5th September 2011 by the European College of Neuropsychopharmacology (ECNP) sheds new light on the state of Europe’s mental and neurological health. The study finds reveal that mental disorders have become Europe’s largest health challenge in the 21st century. The study also highlights that the majority of mental disorders remain untreated. Taken together with the large and increasing number of ‘disorders of the brain’, the true size and burden is even significantly higher.
Cost and impact of non-treating severe mental illnesses (SMIs): The case study of schizophrenia
This study is part of the broader investigation by the European Brain Council (EBC) of the cost of non-treatment of brain disorders in Europe. By providing an extensive review of the case for schizophrenia, it sheds light on the crucial issues to be looked at and provides for a robust methodology that can be translated to the other conditions to be considered in EBC’s broader study.
Country specific papers
After a successful launch of the Cost of Disorders of the Brain in Europe 2010 EBC encourages countries participating in the European study to write country specific papers. In order to facilitate the writing of one paper per country EBC extrapolated the necessary figures and tables for each of the 30 participating European countries. They can be used together with other relevant material and literature concerning the country in question in a country specific paper to be published in a national journal in the national language.
The following countries have published their papers:
Czech Republic
Finland
Switzerland
United Kingdom
As different countries face specific challenges, it is important to consider the national context when advocating for policy change. For this reason, RETHINKING MS also takes an in-depth look at Denmark, Italy, Romania and Spain. The dedicated reports on each country provide a more specific analysis of MS policy, care and support available for people with MS in each country.
RETHINKING MS in Denmark
RETHINKING MS in Italy
RETHINKING MS in Romania
RETHINKING MS in Spain
Resource Allocation for Brain Research in Europe
The EBC has worked with Stockholm Health Economics to review the current level of resource allocation to brain research in the EU. Partly funded by the EC, RABRE sought to build on the EBC’s previous finding that brain diseases represent 35% of the burden of all diseases in Europe. RABRE analysed both private and public funding of brain research in Europe, and funding sources were categorised according to both function and disease target.